Rethinking Infection Diagnostics in Cystic Fibrosis

A dedicated syndicate is connecting academia, industry, and people with cystic fibrosis to advance diagnostic research

1

Cystic fibrosis affects approximately 162,000 individuals globally, leading to recurrent infections and lung damage due to thick mucus.
2

CFTR modulator therapies have improved outcomes for many with cystic fibrosis but have also complicated infection detection and monitoring.
3

Reduced sputum production in patients on CFTR modulators limits the effectiveness of traditional sputum culture for identifying respiratory pathogens.
4

There is a pressing need for innovative diagnostic approaches that utilize alternative sample types and provide timely, actionable information.
5

The CF AMR Syndicate facilitates the development of new diagnostics by connecting innovators with resources and expertise to address unmet needs.

1